Drug news
CHMP recommends Pegasys(Roche) for paediatric use in Hepatitis C
The CHMP recommends Pegasys (peginterferon alfa-2a) from Roche, in combination with ribavirin, be indicated for the treatment of chronic Hepatitis C in treatment-na�ve children and adolescents five years of age and older, who are positive for serum hepatitis-C-virus (HCV) RNA. When deciding to initiate treatment in childhood, it is important to consider growth inhibition induced by combination therapy. The reversibility of growth inhibition is uncertain.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins